Clinical implications of clopidogrel resistance

Area of Science:

• Pharmacology
• Cardiology
• Clinical Medicine

Background:

• Clopidogrel is a widely used antiplatelet medication for coronary artery disease.
• Individual responses to clopidogrel exhibit significant variability.
• Some patients experience adverse events or suboptimal therapeutic effects despite clopidogrel treatment.

Purpose of the Study:

• To review the definition, mechanisms, and clinical implications of clopidogrel resistance.
• To explore strategies for improving patient response to clopidogrel therapy.
• To address the concept of variable response versus clopidogrel resistance.

Main Methods:

• Literature review focusing on clopidogrel pharmacodynamics and clinical outcomes.
• Analysis of studies investigating inter-individual variability in clopidogrel response.
• Examination of current guidelines and recommendations regarding clopidogrel dosing and monitoring.

Main Results:

• There is no universally accepted definition for clopidogrel resistance.
• Lower response to clopidogrel is associated with an increased risk of thrombotic events.
• Current guidelines do not recommend routine platelet function assays for monitoring clopidogrel efficacy.
• Standard clopidogrel dosing regimens (300 mg loading, 75 mg maintenance) are generally advised, though higher loading doses (600 mg) may be beneficial in specific scenarios like percutaneous coronary interventions.

Conclusions:

• The term 'variable response' may be more accurate than 'clopidogrel resistance' due to the normal distribution of drug response.
• Suboptimal response to clopidogrel is linked to adverse cardiovascular outcomes.
• Further research and standardized methods are needed to optimize antiplatelet therapy and patient outcomes.